Giuseppe Banna: 177Lu-PSMA-617 for metastatic prostate cancer in LMICs

Giuseppe Banna, Consultant Medical Oncologist at Portsmouth Hospitals University NHS Trust, shared on LinkedIn:

“In this paper, we explore the practical challenges, opportunities, and future directives for radioligand therapy with 177Lu-PSMA-617 for treating metastatic prostate cancer in low- and middle-income countries (LMICs). With a growing need for cost-effective cancer treatments, this research highlights the potential impact of indigenous production and improved access to advanced therapies.

Thanks to the entire team for their collaboration on this important work!”

177Lu-PSMA-617 for metastatic prostate cancer in India

Authors: Aruni Ghose, Soirindhri Banerjee, Partha S. Choudhury, Akash Maniam, Manoj Gupta, Giuseppe L. Banna, Nikhil Vasdev, Amit Ghose, Vanita Noronha, Swarupa Mitra

Source: Giuseppe Banna/LinkedIn

Giuseppe Banna is a Consultant Medical Oncologist at Portsmouth Hospitals University NHS Trust and the Candiolo Cancer Institute IRCCS. He leads the Translational Research and Clinical Trials Unit for Thoracic Tumors. Additionally, he serves as an Honorary Teacher Practitioner at the Universities of Nottingham and Lincoln, and is affiliated with United Lincolnshire Hospitals NHS Trust.